{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:05:16Z","timestamp":1774368316471,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.imj.2026.100235","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:34:32Z","timestamp":1768581272000},"page":"100235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel use of oral delafloxacin monotherapy in staphylococcal prosthetic valve endocarditis: A case report"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-1491","authenticated-orcid":false,"given":"Antonio","family":"Mastroianni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Vangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Guadagnino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Chidichimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavinia","family":"Berardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.imj.2026.100235_bib0001","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.imj.2026.100235_bib0002","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13318-018-0520-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of delafloxacin","volume":"44","author":"Shiu","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.imj.2026.100235_bib0003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","article-title":"Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.imj.2026.100235_bib0004","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/DDDT.S106071","article-title":"Delafloxacin: design, development and potential place in therapy","author":"Candel","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"10.1016\/j.imj.2026.100235_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and Nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agent Chemother"},{"key":"10.1016\/j.imj.2026.100235_bib0006","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1093\/cid\/ciz003","article-title":"Comparative in vitro activities of new antibiotics for the treatment of skin infections","volume":"68","author":"Shortridge","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.imj.2026.100235_bib0007","doi-asserted-by":"crossref","first-page":"e02609","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agent Chemother"},{"issue":"7","key":"10.1016\/j.imj.2026.100235_bib0008","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Bambeke","year":"2015","journal-title":"Future Microbiol"},{"issue":"8","key":"10.1016\/j.imj.2026.100235_bib0009","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/jcm10081743","article-title":"New-generation antibiotics for treatment of gram-positive infections: a review with a focus on endocarditis and osteomyelitis","volume":"10","author":"Bloem","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.imj.2026.100235_bib0010","article-title":"TAVR Infected Pseudomonas endocarditis': a case report","volume":"9","author":"Essien","year":"2022","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"10.1016\/j.imj.2026.100235_bib0011","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/crj.13262","article-title":"Delafloxacin\u2013A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"15","author":"Millar","year":"2021","journal-title":"Clin Respir J"},{"issue":"6","key":"10.1016\/j.imj.2026.100235_bib0012","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/antibiotics12061078","article-title":"Activity of delafloxacin and comparator fluoroquinolones against multidrug-resistant Pseudomonas aeruginosa in an in vitro cystic fibrosis sputum model","volume":"12","author":"Craddock VD","year":"2023","journal-title":"Antibiotics"},{"issue":"9","key":"10.1016\/j.imj.2026.100235_bib0013","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cmi.2023.04.030","article-title":"Choosing patients over placebos: oral transitional therapy vs. IV-only therapy for bacteraemia and infective endocarditis","volume":"29","author":"Phillips","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.imj.2026.100235_bib0014","doi-asserted-by":"crossref","first-page":"ofac706","DOI":"10.1093\/ofid\/ofac706","article-title":"Can the future of ID escape the inertial dogma of its past The exemplars of shorter is better and oral is the new IV","author":"Davar","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.imj.2026.100235_bib0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cmi.2023.06.021","article-title":"Early switch from intravenous to oral anti-microbial therapy in infectious diseases","volume":"29","author":"Sendi","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.imj.2026.100235_bib0016","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2020.0555","article-title":"Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review","volume":"180","author":"Spellberg","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.imj.2026.100235_bib0017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: Place in therapy and review of microbiologic, clinical and pharmacologic properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect Dis Therapy"},{"issue":"3","key":"10.1016\/j.imj.2026.100235_bib0018","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1078\/1438-4221-00126","article-title":"Treatment of Staphylococcus aureus endocarditis using moxifloxacin","volume":"291","author":"Berrington","year":"2001","journal-title":"Int J Med Microbiol"},{"issue":"1","key":"10.1016\/j.imj.2026.100235_bib0019","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1186\/s12879-025-11098-9","article-title":"Antibiotic adherence and treatment completion associated with partial oral therapy versus all intravenous therapy in patients with serious Staphylococcus aureus infections","volume":"25","author":"Craig","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.imj.2026.100235_bib0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/cid\/ciac714","article-title":"Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs","volume":"76","author":"Wildenthal","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.imj.2026.100235_bib0021","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/ciad666","volume":"79","author":"de Kretser","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Infectious Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772431X26000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772431X26000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:29:29Z","timestamp":1774366169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772431X26000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2772431X26000018"],"URL":"https:\/\/doi.org\/10.1016\/j.imj.2026.100235","relation":{},"ISSN":["2772-431X"],"issn-type":[{"value":"2772-431X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel use of oral delafloxacin monotherapy in staphylococcal prosthetic valve endocarditis: A case report","name":"articletitle","label":"Article Title"},{"value":"Infectious Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imj.2026.100235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100235"}}